The association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity after sipuleucel-T (sip-T) treatment in two phase II clinical studies:  STAMP and STRIDE.

Authors

Daniel Peter Petrylak

Yale Cancer Center, New Haven, CT

Daniel Peter Petrylak , Emmanuel S. Antonarakis , Harini Kandadi , Lawrence Fong , Raymond S. Lance , Tuyen Vu , Nadeem Anwar Sheikh , Neal D. Shore , Charles G. Drake

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 Genitourinary Cancers Symposium

bookmark_border

Boosting long-term immune responses to sipuleucel-T (sip-T) by retreatment of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

First Author: Tomasz M. Beer

insert_chart_outlined

Poster

2017 Genitourinary Cancers Symposium

bookmark_border

A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Fatima Karzai

insert_chart_outlined

Poster

2017 Genitourinary Cancers Symposium

bookmark_border

Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts).

First Author: Eric Jay Small

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.

First Author: Matthew Raymond Smith